Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3241-3249

  Ahlenstiel, Thurid ^a   Pape, Lars ^a   Ehrich, Jochen H H ^a   Kuhlmann, Martin K ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Vivantes Klinikum Friedrichshain   (Germany)

Author keywords

children; chronic kidney disease; hyperphosphataemia; phosphate units; renal diet

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CREATININE; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; SEVELAMER;

ADOLESCENT; ARTICLE; BEHAVIOR CHANGE; CALCIUM BLOOD LEVEL; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; EDUCATION PROGRAM; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MALE; MEAL; MORTALITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PILL; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FOLLOW-UP STUDIES; FOOD HABITS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MEDICATION ADHERENCE; PATIENT SATISFACTION; PHOSPHATES; PROSPECTIVE STUDIES;

EID: 77956633302     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq161     Document Type: Article

References (35)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon, Port FK. Association of elevated serum PO4, Ca × PO4 product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
5. Brancacccio D, Zoccali C. The continuous challenge of cardiovascular and bone disease in uremic patients: clinical consequences of hy-perphosphatemia and advanced therapeutic approaches. J Nephrol 2006; 19: 12-20
6. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2004; 16: 520-528
7. Klaus G, Watson A, Edefoni A et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21: 151-159
8. Sanchez CP. Mineral metabolism and bone abnormalities in children with chronic renal failure. Rev Endocr Metab Disord 2008; 9: 131-137
9. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 2008; 23: 195-207
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
11. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid ar-teriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105
12. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46: S1-S121
13. Blayney MJ, Tentori F. Trends and consequences of mineral bone disorder in haemodialysis patients: lessons from the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Ren Care 2009; 35: 7-13
14. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-38
15. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int 2006; 10: 338-345
16. Kuhlmann MK. Practical approaches to management of hyperpho-sphatemia: can we improve the current situation?. Blood Purif 2007; 25: 120-124
17. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 2007; 20: 295-301
18. Kuhlmann MK, Hoechst S, Landthaler I. Patient empowerment in the management of hyperphosphatemia. Int J Artif Organs 2007; 30: 1008-1013
19. Sämann A, Mühlhauser I, Bender R, Kloos C, Müller UA. Glycemic control and severe hypoglycaemia following training in flexible intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005; 48: 1965-1970
20. Brodehl J, Gellissen K, Weber H.-P. Postnatal development of tubular phosphate reabsorption. Clin Nephrol 1982; 17: 163-171
21. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320: 1110-1113
22. Coladonato JA. Control of hyperphospatemia among patients with ESRD. J Am Soc Nephrol 2005; 16: S107-S114
23. Chertow GM, Burke SK, Raggi P. Selevamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
24. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
25. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyper-phosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE) Study. Kidney Int 2004; 65: 1914-1926
26. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
27. Blaszak RT, Mitsnefes MM, Ilyas M, Salman SD, Belcher SM, Brady DR. Hyperphosphatemia in children receiving peritoneal dialysis\an educational program. Pediatr Nephrol 2005; 20: 967-971
28. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008; 88: 1511-1518
29. Lowe J, Linjawi S, Mensch M, James K, Attia J. Flexible eating and flexible insulin dosing in patients with diabetes: results of an intensive self-management course. Diabetes Res Clin Pract 2008; 80: 439-443
30. Mehta SN, Quinn N, Volkening LK et al. Impact of carbohydrate counting on glycemic control in children with type 1 diabetes. Diabetes Care 2009; 32: 1014-1016
31. Finn WF. Phosphorus management in end-stage renal disease. Semin Dial 2005; 18: 8-12
32. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
33. Spiegel DM, Raggi P, Smits G, Block GA. Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant 2007; 22: 3568-3572
34. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodial-ysis patients. Nephron 2002; 92: 499-500
35. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride. Mechanisms and clinical implications. Kidney Int Suppl 2004; 90: S39-S45